| 000 | 01464 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250517183644.0 | ||
| 264 | 0 | _c20191024 | |
| 008 | 201910s 0 0 eng d | ||
| 022 | _a1365-2982 | ||
| 024 | 7 |
_a10.1111/nmo.13247 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStern, E K | |
| 245 | 0 | 0 |
_aAbnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients. _h[electronic resource] |
| 260 |
_bNeurogastroenterology and motility _c02 2018 |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 | _aEndoscopy, Gastrointestinal |
| 650 | 0 | 4 | _aEsophageal pH Monitoring |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGastroesophageal Reflux _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aManometry |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProton Pump Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aScleroderma, Systemic _xcomplications |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aCarlson, D A | |
| 700 | 1 | _aFalmagne, S | |
| 700 | 1 | _aHoffmann, A D | |
| 700 | 1 | _aCarns, M | |
| 700 | 1 | _aPandolfino, J E | |
| 700 | 1 | _aHinchcliff, M | |
| 700 | 1 | _aBrenner, D M | |
| 773 | 0 |
_tNeurogastroenterology and motility _gvol. 30 _gno. 2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/nmo.13247 _zAvailable from publisher's website |
| 999 |
_c27761356 _d27761356 |
||